MELK-In-7

MELK-In-7 (also known as MELK-IN-17 or MELK-IN-1) is a selective, small-molecule inhibitor of maternal embryonic leucine zipper kinase (MELK), developed through a collaboration between the University of Texas at Austin and MD Anderson Cancer Center. MELK is a serine/threonine kinase that is overexpressed in various aggressive malignancies, including triple-negative breast cancer (TNBC) and glioblastoma multiforme, where it plays a critical role in promoting cancer stem-like cell (CSC) maintenance, epithelial-to-mesenchymal transition (EMT), and tumor metastasis. By targeting MELK, MELK-In-7 suppresses cell proliferation, migration, invasion, and mammosphere formation in TNBC cells, and has demonstrated dose-dependent tumor growth inhibition in preclinical mouse models.

Other names

MELK inhibitor 17Methyl (Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-5-carboxylateNintedanib Impurity Linhibitor 17inhibitor17inhibitor-17